Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 61 AL 75

Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies

Bakota L, Ussif A, Jeserich G, Brandt R.

Mol Cell Neurosci. 2017 Oct;84:132-141. doi: 10.1016/j.mcn.2017.03.003. Epub 2017 Mar 17.

Direct and indirect cost of managing alzheimer's disease and related dementias in the United States

Deb A, Thornton JD, Sambamoorthi U, Innes K.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):189-202. doi: 10.1080/14737167.2017.1313118.

Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease

Faustino C, Rijo P, Reis CP.

Pharmacol Res. 2017 Jun;120:68-87. doi: 10.1016/j.phrs.2017.03.020. Epub 2017 Mar 27.

Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G.

Curr Alzheimer Res. 2017;14(11):1155-1163. doi: 10.2174/1567205014666170329113007.

Preclinical to phase II amyloid beta (A(β)) peptide modulators under investigation for Alzheimer's disease

Parsons CG, Rammes G.

Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832.

Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimer's Disease

Racine E, Aspler J, Forlini C, Chandler JA.

Kennedy Inst Ethics J. 2017;27(1):1-41. doi: 10.1353/ken.2017.0002.

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li Q, Yang H, Chen Y, Sun H.

Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial

Brueggen K, Kasper E, Ochmann S, Pfaff H, Webel S, Schneider W, Teipel S.

J Alzheimers Dis. 2017;57(4):1315-1324. doi: 10.3233/JAD-160771.

Alzheimer's disease: where next for anti-amyloid therapies?

Hardy J, De Strooper B.

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials

Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, AlSafadi AM.

BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease

Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N, Valencia-Olvera AC, LaDu MJ.

J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7.

Editorial (Thematic Issue: Hybrid Compounds as Multitarget Agents in Medicinal Chemistry - Part II)

Scotti L, Mendonça-Junior FJ, Scotti MT.

Curr Top Med Chem. 2017;17(9):957-958. doi: 10.2174/156802661709170213205211.

The Role of ADAM10 in Alzheimer's Disease

Yuan XZ, Sun S, Tan CC, Yu JT, Tan L.

J Alzheimers Dis. 2017;58(2):303-322. doi: 10.3233/JAD-170061.

Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease

Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, Sharma RK, Agrawal M, Mishra A, Dua K.

CNS Neurosci Ther. 2017 Jun;23(6):457-461. doi: 10.1111/cns.12696. Epub 2017 Apr 17.

Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment

Fessel WJ.

Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias